Abbott India Ltd
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE 500 BSE Healthcare BSE 200 BSE Dollex 200 Nifty 500
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/OP |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| New Product Launches count ・Standalone data |
|
|||||||||
| Number of Employees count ・Standalone data |
||||||||||
| Brands in Top 100 of IPM count ・Standalone data |
||||||||||
| Brands Portfolio Size count ・Standalone data |
||||||||||
| Number of Distributors/Stockists count ・Standalone data |
||||||||||
| Brands Ranked #1 in Participated Markets count ・Standalone data |
||||||||||
| In-House Manufacturing Share (Goa Plant % of Net Sales) % ・Standalone data |
||||||||||
| Tablet Production Volume Growth % ・Standalone data |
||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
20 Jul - Newspaper Advertisement for Eighty-second Annual General Meeting, E-voting facility and Dividend.
-
Communication Providing The Weblink Including Path Of Annual Report.
20 Jul - Abbott India shared the 2025-26 annual report web-link under SEBI Regulation 36.
-
Business Responsibility and Sustainability Reporting (BRSR)
20 Jul - Abbott India submitted FY2025-26 BRSR with independent assurance statement on July 20, 2026.
-
Annual General Meeting On August 13, 2026.
20 Jul - Abbott India AGM on Aug 13, 2026; proposes ₹525 final and ₹131 special dividend.
- Reg. 34 (1) Annual Report. 20 Jul
Annual reports
-
Financial Year 2026
from bse
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Sep 2022TranscriptPPTREC
-
Jun 2021TranscriptPPT
Abbott Group:[1]
The company is a part of Abbott Laboratories, USA which has a presence in 160 countries with leading medical devices, diagnostics, nutrition products, and branded generic medicines.